In our study, two patients were treated with the CD38-targeting antibody Daratumumab and exhibited sufficient antibody production; nevertheless, there was one Daratumumab-treated lymphoma patient who did not respond to the vaccination. This evidence concerns the gene CD38 and lymphoma.